Multi-omics Startup Pleno Inc. Announces $15 Million in Pre-Series A Funding
Summary
Mr. Lucier has also made a substantial investment in the company as part of the Pre-Series A funding.Pleno has developed a unique enabling technology called Hypercoding, which leverages signal processing techniques derived from the telecom industry to deliver ultra-high plexity targeted biological information including DNA, RNA, methylation, and proteomic content at unprecedented scale, precision, and performance. "The COVID-19 pandemic demonstrated the limitations of our current biological research and testing paradigms in terms of capability, scalability, throughput, and cost," said Pieter van Rooyen, Founder and Chief Executive Officer at Pleno. "Our technology was born from the desire to enable the simultaneous and rapid detection of more targets, from more samples at a dramatically lower cost, which we believe has the potential to democratize clinical multi-omics and ultimately transform human health. ""Ive known Pieter for years and hes built a team that brings rich and varied experience in genomics, biochemistry, and telecom coding algorithms," said Kim Kamdar, Partner at Medical Excellence Capital and Board Member at Pleno. The companys proprietary Hypercoding technology leverages signal processing techniques from the telecommunications industry to deliver targeted biological information at unprecedented scale, precision, and performance.